pharmaceutical preparations

Summary

Summary: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.

Top Publications

  1. ncbi Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics
    Christoph Steinbeck
    Cologne University Bioinformatics Center CUBIC, Germany
    Curr Pharm Des 12:2111-20. 2006
  2. pmc DrugBank 3.0: a comprehensive resource for 'omics' research on drugs
    Craig Knox
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 39:D1035-41. 2011
  3. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
  4. pmc Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
  5. ncbi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
  6. pmc DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
  7. pmc A side effect resource to capture phenotypic effects of drugs
    Michael Kuhn
    Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
    Mol Syst Biol 6:343. 2010
  8. ncbi Relating protein pharmacology by ligand chemistry
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St, San Francisco California 94143 2550, USA
    Nat Biotechnol 25:197-206. 2007
  9. pmc Prediction of drug-target interaction networks from the integration of chemical and genomic spaces
    Yoshihiro Yamanishi
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611 0011, Japan
    Bioinformatics 24:i232-40. 2008
  10. ncbi Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance
    Dana W Kolpin
    US Geological Survey, Iowa City, Iowa 52244, USA
    Environ Sci Technol 36:1202-11. 2002

Detail Information

Publications315 found, 100 shown here

  1. ncbi Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics
    Christoph Steinbeck
    Cologne University Bioinformatics Center CUBIC, Germany
    Curr Pharm Des 12:2111-20. 2006
    ..This article introduces the CDK's new QSAR capabilities and the recently introduced interface to statistical software...
  2. pmc DrugBank 3.0: a comprehensive resource for 'omics' research on drugs
    Craig Knox
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 39:D1035-41. 2011
    ..0 represents the result of 2 years of manual annotation work aimed at making the database much more useful for a wide range of 'omics' (i.e. pharmacogenomic, pharmacoproteomic, pharmacometabolomic and even pharmacoeconomic) applications...
  3. ncbi Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    C A Lipinski
    Central Research Division, Pfizer Inc, Groton, CT 06340, USA
    Adv Drug Deliv Rev 46:3-26. 2001
    ..Recent work on linear free energy relationships and Log P approaches are critically reviewed. Useful predictions are possible in closely related analog series when coupled with experimental thermodynamic solubility measurements...
  4. pmc Predicting new molecular targets for known drugs
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, California 94143 2550, USA
    Nature 462:175-81. 2009
    ..The chemical similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs...
  5. ncbi Drug target identification using side-effect similarity
    Monica Campillos
    European Molecular Biology Laboratory EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Science 321:263-6. 2008
    ..Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs...
  6. pmc DrugBank: a knowledgebase for drugs, drug actions and drug targets
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 36:D901-6. 2008
    ..DrugBank has also significantly improved the power and simplicity of its structure query and text query searches. DrugBank is available at http://www.drugbank.ca...
  7. pmc A side effect resource to capture phenotypic effects of drugs
    Michael Kuhn
    Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
    Mol Syst Biol 6:343. 2010
    ..We illustrate the potential of SIDER with a number of analyses. The resource is freely available for academic research at http://sideeffects.embl.de...
  8. ncbi Relating protein pharmacology by ligand chemistry
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th St, San Francisco California 94143 2550, USA
    Nat Biotechnol 25:197-206. 2007
    ..These predictions were subsequently confirmed experimentally. Relating receptors by ligand chemistry organizes biology to reveal unexpected relationships that may be assayed using the ligands themselves...
  9. pmc Prediction of drug-target interaction networks from the integration of chemical and genomic spaces
    Yoshihiro Yamanishi
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto 611 0011, Japan
    Bioinformatics 24:i232-40. 2008
    ..Therefore, there is a strong incentive to develop new methods capable of detecting these potential drug-target interactions efficiently...
  10. ncbi Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance
    Dana W Kolpin
    US Geological Survey, Iowa City, Iowa 52244, USA
    Environ Sci Technol 36:1202-11. 2002
    ....
  11. pmc STITCH 2: an interaction network database for small molecules and proteins
    Michael Kuhn
    Biotechnology Center, TU Dresden, 01062 Dresden, Germany
    Nucleic Acids Res 38:D552-6. 2010
    ..STITCH 2.0 connects proteins from 630 organisms to over 74,000 different chemicals, including 2200 drugs. STITCH can be accessed at http://stitch.embl.de/...
  12. pmc Benchmarking sets for molecular docking
    Niu Huang
    Department of Pharmaceutical Chemistry, University of California San Francisco, QB3 Building, 1700 4th Street, Box 2550, San Francisco, California 94143 2550, USA
    J Med Chem 49:6789-801. 2006
    ..DUD is freely available online as a benchmarking set for docking at http://blaster.docking.org/dud/...
  13. pmc An overview of the PubChem BioAssay resource
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 38:D255-66. 2010
    ..In this work, we describe the PubChem BioAssay database, including data model, bioassay deposition and utilities that PubChem provides for searching, downloading and analyzing the biological activity information contained therein...
  14. pmc Update of TTD: Therapeutic Target Database
    Feng Zhu
    Department of Pharmacy and Computation and Systems Biology, Center for Computational Science and Engineering, Singapore MIT Alliance, National University of Singapore, Singapore
    Nucleic Acids Res 38:D787-91. 2010
    ..This database can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD.asp...
  15. pmc Virtual screening of chemical libraries
    Brian K Shoichet
    Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, California 94143 2240, USA
    Nature 432:862-5. 2004
    ....
  16. ncbi ADMET in silico modelling: towards prediction paradise?
    Han van de Waterbeemd
    Pfizer Global Research and Development, PDM, Sandwich, Kent CT13 9NJ, UK
    Nat Rev Drug Discov 2:192-204. 2003
    ..Here, we describe how in silico approaches will further increase our ability to predict and model the most relevant pharmacokinetic, metabolic and toxicity endpoints, thereby accelerating the drug discovery process...
  17. pmc Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
    Yoshihiro Yamanishi
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, Institut Curie, F 75248, INSERM U900, F 75248, Paris, France
    Bioinformatics 26:i246-54. 2010
    ..There is therefore a strong incentive to develop new methods capable of detecting these potential drug-target interactions efficiently...
  18. pmc Exploiting drug-disease relationships for computational drug repositioning
    Joel T Dudley
    Stanford University, Stanford, CA, USA
    Brief Bioinform 12:303-11. 2011
    ..Newer algorithms for computational drug repositioning will likely span these two axes, will take advantage of newer types of molecular measurements, and will certainly play a role in reducing the global burden of disease...
  19. pmc PubChem: a public information system for analyzing bioactivities of small molecules
    Yanli Wang
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
    Nucleic Acids Res 37:W623-33. 2009
    ..Most of the tools described in this work can be directly accessed at http://pubchem.ncbi.nlm.nih.gov/assay/. URLs for accessing other tools described in this work are specified individually...
  20. ncbi Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data
    Thomas Heberer
    Institute of Food Chemistry, Technical University of Berlin, Sekr TIB 4 3 1, Gustav Meyer Allee 25, 13355 Berlin, Germany
    Toxicol Lett 131:5-17. 2002
    ..To date, only in a few cases PhACs have also been detected at trace-levels in drinking water samples...
  21. pmc From genomics to chemical genomics: new developments in KEGG
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto 611 0011, Japan
    Nucleic Acids Res 34:D354-7. 2006
    ..Additionally, drug information is now stored separately and linked to new KEGG DRUG structure maps...
  22. ncbi Ecotoxicology of human pharmaceuticals
    Karl Fent
    University of Applied Sciences Basel, Institute of Environmental Technology, Muttenz, Switzerland
    Aquat Toxicol 76:122-59. 2006
    ..This will allow better and comprehensive risk assessments of pharmaceuticals in the future...
  23. ncbi Appropriate prescribing in elderly people: how well can it be measured and optimised?
    Anne Spinewine
    Center for Clinical Pharmacy, School of Pharmacy, Universite Catholique de Louvain, Brussels, Belgium
    Lancet 370:173-84. 2007
    ....
  24. pmc Chemical Entities of Biological Interest: an update
    Paula de Matos
    Chemoinformatics and Metabolism Team, European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK
    Nucleic Acids Res 38:D249-54. 2010
    ....
  25. pmc Extracting medication information from clinical text
    Ozlem Uzuner
    Department of Information Studies, University at Albany, State University of New York, Albany, NY, USA
    J Am Med Inform Assoc 17:514-8. 2010
    ..However, they are limited in recognizing duration and reason fields and would benefit from future research...
  26. ncbi Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
    Paul Morgan
    Pfizer, Departments of Pharmacokinetics, Dynamics and Metabolism, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Drug Discov Today 17:419-24. 2012
    ....
  27. pmc ChEBI: a database and ontology for chemical entities of biological interest
    Kirill Degtyarenko
    European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
    Nucleic Acids Res 36:D344-50. 2008
    ..ChEBI includes an ontological classification, whereby the relationships between molecular entities or classes of entities and their parents and/or children are specified. ChEBI is available online at http://www.ebi.ac.uk/chebi/..
  28. pmc Identifying the proteins to which small-molecule probes and drugs bind in cells
    Shao En Ong
    Proteomics Platform, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 106:4617-22. 2009
    ..Here, we describe in full detail the application of the method to identify targets of kinase inhibitors and immunophilin binders...
  29. ncbi Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast
    Ainslie B Parsons
    Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario M5G 1L6, Canada
    Cell 126:611-25. 2006
    ..This compendium should serve as a valuable key for interpreting cellular effects of novel compounds with similar activities...
  30. ncbi Functional classification of drugs by properties of their pairwise interactions
    Pamela Yeh
    Bauer Center for Genomics Research, Harvard University, 7 Divinity Avenue, Cambridge, Massachusetts 02138, USA
    Nat Genet 38:489-94. 2006
    ..This network approach provides a new conceptual framework for understanding the functional mechanisms of drugs and their cellular targets and can be applied in systems intractable to mutant screening, biochemistry or microscopy...
  31. pmc KEGG for linking genomes to life and the environment
    Minoru Kanehisa
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Uji, Kyoto, Japan
    Nucleic Acids Res 36:D480-4. 2008
    ..KEGG DRUG contains all approved drugs in the US and Japan, and KEGG DISEASE is a new database linking disease genes, pathways, drugs and diagnostic markers...
  32. ncbi Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment
    Lúcia H M L M Santos
    REQUIMTE, Faculty of Pharmacy, University of Porto Rua Anibal Cunha, 164, 4050 047 Porto, Portugal
    J Hazard Mater 175:45-95. 2010
    ..An extensive review of existing data in the form of tables, encompassing many therapeutic classes is presented...
  33. pmc Chemical substructures that enrich for biological activity
    Justin Klekota
    Harvard University Graduate Biophysics Program, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
    Bioinformatics 24:2518-25. 2008
    ..This has led to the claim of 'privileged' substructures which are predisposed to bioactivity. Because bias in screening library construction could explain this phenomenon, the existence of privilege has been controversial...
  34. pmc IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data
    Joanna L Sharman
    University BHF Centre for Cardiovascular Science, The Queen s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK
    Nucleic Acids Res 39:D534-8. 2011
    ..The database is freely available at http://www.iuphar-db.org...
  35. pmc DrugBank: a comprehensive resource for in silico drug discovery and exploration
    David S Wishart
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
    Nucleic Acids Res 34:D668-72. 2006
    ..DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/...
  36. ncbi The many roles of computation in drug discovery
    William L Jorgensen
    Department of Chemistry, Yale University, New Haven, CT 06520 8107, USA
    Science 303:1813-8. 2004
    ..Particular emphasis is placed on virtual screening, de novo design, evaluation of drug-likeness, and advanced methods for determining protein-ligand binding...
  37. pmc Supervised prediction of drug-target interactions using bipartite local models
    Kevin Bleakley
    Mines ParisTech, Centre for Computational Biology, Fontainebleau, France
    Bioinformatics 25:2397-403. 2009
    ..This, however, remains extremely challenging due to, amongst other things, the rarity of known drug-target interactions...
  38. ncbi Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands
    Anne J Leendertse
    Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Arch Intern Med 168:1890-6. 2008
    ..Furthermore, little information exists on potential risk factors associated with preventable medication-related hospitalizations...
  39. ncbi Determinants of under-reporting of adverse drug reactions: a systematic review
    Elena Lopez-Gonzalez
    Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain
    Drug Saf 32:19-31. 2009
    ..This result may have important implications in terms of public health, if knowledge and attitudes are viewed as potentially modifiable factors...
  40. ncbi Medication errors and adverse drug events in pediatric inpatients
    R Kaushal
    Children's Hospital, Enders 609, Longwood Avenue, Boston, MA 02115, USA
    JAMA 285:2114-20. 2001
    ..CONCLUSIONS: Medication errors are common in pediatric inpatient settings, and further efforts are needed to reduce them...
  41. pmc Systematic evaluation of drug-disease relationships to identify leads for novel drug uses
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 86:507-10. 2009
    ..When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials...
  42. pmc DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome
    Heng Luo
    Bio X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    Nucleic Acids Res 39:W492-8. 2011
    ..This server is freely available at http://cpi.bio-x.cn/drar/...
  43. ncbi The influence of drug-like concepts on decision-making in medicinal chemistry
    Paul D Leeson
    AstraZeneca R and D Charnwood, Bakewell Road, Loughborough LE15 5RH, UK
    Nat Rev Drug Discov 6:881-90. 2007
    ..Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making...
  44. ncbi Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
    P Ertl
    Cheminformatics, Novartis Pharma AG, WKL 490 4 35, CH 4002 Basel, Switzerland
    J Med Chem 43:3714-7. 2000
    ..This article describes the new methodology and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration...
  45. ncbi Aging biology and geriatric clinical pharmacology
    Allan J McLean
    Director, National Ageing Research Institute, P O Box 31, Parkville, VIC Australia
    Pharmacol Rev 56:163-84. 2004
    ..Even so, therapeutic advances generally may convert healthy longevity from an asset of fortunate individuals into a general social benefit...
  46. ncbi Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database
    Ana Szarfman
    Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Drug Saf 25:381-92. 2002
    ..The application of these tools may ultimately improve usage recommendations...
  47. pmc Pharmaceuticals and personal care products in the environment: what are the big questions?
    Alistair B A Boxall
    Environment Department, University of York, Heslington, York, United Kingdom
    Environ Health Perspect 120:1221-9. 2012
    ..Over the past 10-15 years, a substantial amount of work has been done by the scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals and personal care products (PPCPs) in the environment...
  48. pmc Predicting drug-target interaction networks based on functional groups and biological features
    Zhisong He
    CAS MPG Partner Institute of Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    PLoS ONE 5:e9603. 2010
    ..As a complement, the in silico prediction methods can provide us with very useful information in a timely manner...
  49. pmc A computational approach to finding novel targets for existing drugs
    Yvonne Y Li
    Canada s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    PLoS Comput Biol 7:e1002139. 2011
    ..Novel interactions discovered may lead to the drug being repositioned as a therapeutic treatment for its off-target's associated disease, added insight into the drug's mechanism of action, and added insight into the drug's side effects...
  50. pmc Predicting drug side-effect profiles: a chemical fragment-based approach
    Edouard Pauwels
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, France
    BMC Bioinformatics 12:169. 2011
    ....
  51. ncbi A robustness-based approach to systems-oriented drug design
    Hiroaki Kitano
    Sony Computer Science Laboratories Inc, 3 14 13 Higashi Gotanda, Shinagawa, Tokyo 141 0022, Japan
    Nat Rev Drug Discov 6:202-10. 2007
    ....
  52. ncbi Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
    Christopher J H Porter
    Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Nat Rev Drug Discov 6:231-48. 2007
    ....
  53. ncbi Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure
    Andreas Bender
    Lead Finding Platform, Novartis Institutes for BioMedical Research Inc 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA
    ChemMedChem 2:861-73. 2007
    ..In addition, models such as the ones presented here can be used for compound profiling in all development stages...
  54. ncbi Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
    Nicola J Hewitt
    Scientific Writing Services, Wingertstrasse, Erzhausen, Germany
    Drug Metab Rev 39:159-234. 2007
    ..We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process...
  55. ncbi Evolutionary conservation of human drug targets in organisms used for environmental risk assessments
    Lina Gunnarsson
    Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Box 434, SE 405 30 Goteborg, Sweden
    Environ Sci Technol 42:5807-13. 2008
    ..Moreover, we suggest that the results can be used to interpret the relevance of existing ecotoxicity data...
  56. ncbi Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada
    Glen R Boyd
    Department of Civil and Environmental Engineering, Tulane University, New Orleans, LA 70118, USA
    Sci Total Environ 311:135-49. 2003
    ..In addition, our study demonstrates the importance of obtaining data on removal mechanisms and byproducts associated with PPCPs and other endocrine-disrupting chemicals in drinking water and sewage treatment processes...
  57. pmc SMPDB: The Small Molecule Pathway Database
    Alex Frolkis
    Department of Computing Science, University of Alberta, Edmonton, AB, Canada
    Nucleic Acids Res 38:D480-7. 2010
    ..Gene, metabolite and protein concentration data can also be visualized through SMPDB's mapping interface. All of SMPDB's images, image maps, descriptions and tables are downloadable. SMPDB is available at: http://www.smpdb.ca...
  58. pmc Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments
    Roger Bate
    American Enterprise Institute, Washington, D C, USA
    Malar J 9:157. 2010
    ..Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed...
  59. ncbi 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries
    Paul D Dobson
    School of Chemistry and The Manchester Interdisciplinary Biocentre, The University of Manchester, 131 Princess St, Manchester M1 7DN, UK
    Drug Discov Today 14:31-40. 2009
    ....
  60. pmc PharmGKB: the Pharmacogenetics Knowledge Base
    Micheal Hewett
    Stanford Medical Informatics, 251 Campus Drive, MSOB X 215, Stanford, CA 94305 5479, USA
    Nucleic Acids Res 30:163-5. 2002
    ..The PharmGKB project was initiated in April 2000 and the first version of the knowledge base went online in February 2001...
  61. pmc SuperTarget and Matador: resources for exploring drug-target relationships
    Stefan Günther
    Structural Bioinformatics Group, Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 36:D919-22. 2008
    ..SuperTarget and Matador are available at http://insilico.charite.de/supertarget and http://matador.embl.de...
  62. ncbi Prevalence, incidence and nature of prescribing errors in hospital inpatients: a systematic review
    Penny J Lewis
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Drug Saf 32:379-89. 2009
    ..Future research should address the wide disparity of data-collection methods and definitions that bedevils comparison of error rates or meta-analysis of different studies...
  63. ncbi Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water
    Mark J Benotti
    Applied Research and Development Center, Southern Nevada Water Authority, P O Box 99954, Las Vegas, Nevada 89193 9954, USA
    Environ Sci Technol 43:597-603. 2009
    ..Atenolol, atrazine, DEET, estrone, meprobamate, and trimethoprim can serve as indicator compounds representing potential contamination from other pharmaceuticals and EDCs and can gauge the efficacy of treatment processes...
  64. pmc PROMISCUOUS: a database for network-based drug-repositioning
    Joachim von Eichborn
    Charite Universitatsmedizin Berlin, Institute for Physiology, Structural Bioinformatics Group, Lindenberger Weg 80, 13125 Berlin, Germany
    Nucleic Acids Res 39:D1060-6. 2011
    ..This network-based approach can provide a starting point for drug-repositioning. PROMISCUOUS is publicly available at http://bioinformatics.charite.de/promiscuous...
  65. ncbi Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry
    Miklos Feher
    SignalGene Inc, 335 Laird Road, Unit 2, Guelph, Ontario, N1G 4P7, Canada
    J Chem Inf Comput Sci 43:218-27. 2003
    ..It is suggested that by mimicking certain distribution properties of natural compounds, combinatorial products might be made that are substantially more diverse and have greater biological relevance...
  66. ncbi Drug-related problems in hospitals: a review of the recent literature
    Anita Krähenbühl-Melcher
    Hospital Pharmacy, Regionalspital Emmental, Burgdorf, Switzerland
    Drug Saf 30:379-407. 2007
    ....
  67. ncbi Comparison of support vector machine and artificial neural network systems for drug/nondrug classification
    Evgeny Byvatov
    Institut für Organische Chemie und Chemische Biologie, Johann Wolfgang Goethe Universitat, Marie Curie Strasse 11, D 60439 Frankfurt, Germany
    J Chem Inf Comput Sci 43:1882-9. 2003
    ..The theory of SVM and ANN training is briefly reviewed...
  68. pmc Mining FDA drug labels using an unsupervised learning technique--topic modeling
    Halil Bisgin
    Department of Information Science, University of Arkansas at Little Rock, 2801 S, University Ave, Little Rock, AR 72204 1099, USA
    BMC Bioinformatics 12:S11. 2011
    ..Consequently, this task has largely relied on the manual reading of the full text by experts, which is time consuming and labor intensive...
  69. pmc Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems
    Kirsten K Viktil
    Diakonhjemmet Hospital Pharmacy, Faculty of Medicine, University of Oslo, Oslo, Norway
    Br J Clin Pharmacol 63:187-95. 2007
    ..To investigate whether polypharmacy defined as a definite number of drugs is a suitable indicator for describing the risk of occurrence of drug-related problems (DRPs) in a hospital setting...
  70. pmc Pharmaceuticals and personal care products in the environment: agents of subtle change?
    C G Daughton
    Environmental Sciences Division, U S Environmental Protection Agency, ORD NERL, Las Vegas, Nevada 89119, USA
    Environ Health Perspect 107:907-38. 1999
    ..This review attempts to synthesize the literature on environmental origin, distribution/occurrence, and effects and to catalyze a more focused discussion in the environmental science community...
  71. ncbi Antibody-drug conjugates for the treatment of cancer
    John A Flygare
    Department of Discovery Chemistry, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Chem Biol Drug Des 81:113-21. 2013
    ..Future directions in the field are proposed...
  72. pmc Priority medicines for maternal and child health: a global survey of national essential medicines lists
    Suzanne Hill
    Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    PLoS ONE 7:e38055. 2012
    ..The objective of this study was to examine the occurrence of these priority medicines on national essential medicines lists...
  73. ncbi Uptake and depuration of pharmaceuticals in aquatic invertebrates
    Melanie Meredith-Williams
    Environment Department, University of York, Heslington, York YO10 5DD, UK
    Environ Pollut 165:250-8. 2012
    ..BCFs of the pharmaceuticals for each organism were correlated to the pH-corrected liposome-water partition coefficient of the pharmaceuticals...
  74. ncbi Enabling clearance predictions to emerge from in silico actions of quasi-autonomous hepatocyte components
    Shahab Sheikh-Bahaei
    Joint Graduate Group in Bioengineering, University of California, Berkeley, California, USA
    Drug Metab Dispos 39:1910-20. 2011
    ..ISHC details during simulations stand as a mechanistic hypothesis of how clearance phenomena emerge during in vitro experiments...
  75. ncbi Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities
    Toshiro Niwa
    Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Higashi Tamagawa Gakuen, Machida, Tokyo, Japan
    Curr Drug Metab 12:549-69. 2011
    ..The present information gives insight into the contribution of stereoselectivity to metabolism mediated by P450s and the risk of adverse drug-drug interactions due to stereoselectivity...
  76. ncbi An algorithmic framework for predicting side effects of drugs
    Nir Atias
    Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel
    J Comput Biol 18:207-18. 2011
    ..Our method thus represents a promising step toward shortcutting the process and reducing the cost of side effect elucidation...
  77. pmc BDDCS applied to over 900 drugs
    Leslie Z Benet
    Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, 94143 0912, USA
    AAPS J 13:519-47. 2011
    ..The influence of several measured and in silico parameters in the process of BDDCS category assignment is discussed in detail...
  78. ncbi Analysis of chemical and biological features yields mechanistic insights into drug side effects
    Miquel Duran-Frigola
    Joint IRB BSC Program in Computational Biology, Institute for Research in Biomedicine, c Baldiri Reixac 10 12, 08028 Barcelona, Spain
    Chem Biol 20:594-603. 2013
    ..Overall, we provide mechanistic insights for most SEs and emphasize the need to blend biology and chemistry to surpass intricate phenomena not captured in the molecular biology view...
  79. ncbi Mass spectrometry imaging for drug distribution studies
    Brendan Prideaux
    Novartis Institutes for BioMedical Research, Basel, Switzerland Public Health Research Institute, Newark, NJ 07103, USA
    J Proteomics 75:4999-5013. 2012
    ..In this article we review the different MSI technologies that have been applied to the imaging of pharmaceuticals. Recent technical advances, applications and current analytical limitations are discussed...
  80. ncbi Adverse drug reactions in childhood: a review of prospective studies and safety alerts
    A Clavenna
    Laboratory for Mother and Child Health, Department of Public Health, Mario Negri Institute for Pharmacological Research, 20156 Milan MI, Italy
    Arch Dis Child 94:724-8. 2009
    ..To assess the incidence of adverse drug reactions (ADRs) in the paediatric population and the safety alerts concerning children and adolescents issued by international drug regulatory agencies since 2001...
  81. pmc Building the process-drug-side effect network to discover the relationship between biological processes and side effects
    Sejoon Lee
    Bio and Brain Engineering Department, KAIST, Daejeon 305 701, South Korea
    BMC Bioinformatics 12:S2. 2011
    ..To the best of our knowledge, the relationship between biological processes and side effects of drugs has not yet been systematically researched...
  82. ncbi Global mapping of pharmacological space
    Gaia V Paolini
    The Department of Knowledge Discovery, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK
    Nat Biotechnol 24:805-15. 2006
    ..The relationships between proteins, chemical structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity...
  83. ncbi Diagnosing the decline in pharmaceutical R&D efficiency
    Jack W Scannell
    Sanford C Bernstein Limited, 50 Berkeley Street, Mayfair Place, London W1J 8SB, UK
    Nat Rev Drug Discov 11:191-200. 2012
    ..Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency...
  84. ncbi Impact of solvent conditions on separation and detection of basic drugs by micro liquid chromatography-mass spectrometry under overloading conditions
    Birthe Schubert
    Institute of Legal Medicine, Innsbruck Medical University, Muellerstrasse 44, 6020 Innsbruck, Austria
    J Chromatogr A 1218:3413-22. 2011
    ..Applications of μLC/MS for the qualitative and quantitative analysis of clinical and forensic toxicological samples are presented...
  85. ncbi Observational study of potential risk factors of medication administration errors
    Edgar Tissot
    Pharmacy Department, Besancon University Hospital, Boulevard Fleming, 25030 Besancon, France
    Pharm World Sci 25:264-8. 2003
    ..The aims of this observational study were to assess the rate and the potential clinical significance of MAEs and to determine the associated risk factors...
  86. pmc Relating drug-protein interaction network with drug side effects
    Sayaka Mizutani
    Bioinformatics Center, Institute for Chemical Research, Kyoto University, Gokasho Uji, Kyoto 611 0011, Japan
    Bioinformatics 28:i522-i528. 2012
    ....
  87. pmc The chemical basis of pharmacology
    Michael J Keiser
    Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158 2558, USA
    Biochemistry 49:10267-76. 2010
    ..The bases for these new methods, some of their successes and liabilities, and new opportunities for their use are described...
  88. ncbi Stability of protein pharmaceuticals: an update
    Mark Cornell Manning
    Legacy BioDesign LLC, Johnstown, Colorado 80534, USA
    Pharm Res 27:544-75. 2010
    ....
  89. ncbi A framework to assess the translation of safety pharmacology data to humans
    Jean Pierre Valentin
    Safety Assessment UK, AstraZeneca R and D Alderley Park, Macclesfield, SK10 4TG, United Kingdom
    J Pharmacol Toxicol Methods 60:152-8. 2009
    ..This task requires the collaboration and agreement of pharmaceutical companies to share data anonymously on proprietary and candidate drugs...
  90. ncbi Recent patents review on intranasal administration for CNS drug delivery
    Viral Jogani
    TIFAC CORE IN NDDS, Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, Gujarat State, India
    Recent Pat Drug Deliv Formul 2:25-40. 2008
    ..A critical review of recent patents claiming different approaches for enhanced brain delivery through the nasal route will help in determining the focus of this promising area of research...
  91. ncbi Nuclear receptors and drug disposition gene regulation
    Rommel G Tirona
    Department of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Pharm Sci 94:1169-86. 2005
    ..Finally, we discuss some current topics and themes in nuclear receptor-mediated regulation of drug metabolizing enzymes and drug transporters...
  92. ncbi Analysis of 70 Environmental Protection Agency priority pharmaceuticals in water by EPA Method 1694
    Imma Ferrer
    Center for Environmental Mass Spectrometry, Dpt Civil, Environmental and Architectural Engineering, University of Colorado, Boulder, 80309, USA
    J Chromatogr A 1217:5674-86. 2010
    ....
  93. ncbi Human pharmaceuticals in the aquatic environment: a challenge to Green Chemistry
    Sushil K Khetan
    Department of Chemistry, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
    Chem Rev 107:2319-64. 2007
  94. pmc Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy
    Christian G Daughton
    Environmental Chemistry Branch, Environmental Sciences Division National Exposure Research Laboratory, Office of Research and Development, U S Environmental Protection Agency, Las Vegas, Nevada 89119, USA
    Environ Health Perspect 111:757-74. 2003
    ..A major objective is to generate an active dialog or debate across the many disciplines that must become actively involved to design and implement a successful approach to life-cycle stewardship of PPCPs...
  95. ncbi Bioequivalence approaches for highly variable drugs and drug products
    Sam H Haidar
    Office of Generic Drugs, Food and Drug Administration, 7500 Standish Place, Rockville, Maryland, 20855, USA
    Pharm Res 25:237-41. 2008
    ..A partial replicated-treatment design with this new data analysis methodology will thus provide a more efficient design for BE studies with highly variable drugs and drug products...
  96. pmc Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS
    Gabriel A Silva
    Departments of Bioengineering and Ophthalmology, and Neurosciences Program, University of California San Diego, 9415 Campus Point Drive, La Jolla, CA 92037 0946, USA
    BMC Neurosci 9:S4. 2008
    ..This brief review introduces emerging work in this area and summarizes a number of example applications to CNS cancers, gene therapy, and analgesia...
  97. ncbi Determination of multiple pharmaceutical classes in surface and ground waters by liquid chromatography-ion trap-tandem mass spectrometry
    Svetlana Grujic
    Department of Analytical Chemistry, Faculty of Technology and Metallurgy, University of Belgrade, Belgrade, Serbia
    J Chromatogr A 1216:4989-5000. 2009
    ..Confirmation of the positive results was performed by repeated injection of the positive sample extracts using confirmatory method with additional transitions...
  98. pmc STITCH: interaction networks of chemicals and proteins
    Michael Kuhn
    European Molecular Biology Laboratory, Meyerhofstrasse 1, 69117 Heidelberg, Germany
    Nucleic Acids Res 36:D684-8. 2008
    ..5 million genes across 373 genomes and their interactions contained in the STRING database. STITCH is available at http://stitch.embl.de/...
  99. pmc Finding complex biological relationships in recent PubMed articles using Bio-LDA
    Huijun Wang
    School of Informatics and Computing, Indiana University, Bloomington, Indiana, United States of America
    PLoS ONE 6:e17243. 2011
    ..This combined approach offers new opportunities for knowledge discovery in many areas of biology including target identification, lead hopping and drug repurposing...
  100. ncbi Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital
    Jimmy Jose
    Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576 104, Karnataka, India
    Pharmacol Res 54:226-33. 2006
    ..Our evaluations revealed opportunities for interventions especially for the preventable ADRs to ensure safer drug use...
  101. ncbi Sampling for PPCPs in wastewater systems: comparison of different sampling modes and optimization strategies
    Christoph Ort
    The University of Queensland, Advanced Water Management Centre, QLD 4072, Australia
    Environ Sci Technol 44:6289-96. 2010
    ....

Research Grants70

  1. Mechanisms of Manganese Neurotoxicity
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2013
    ..the use of manganese as a gasoline additive, and in welding, metal industries, pesticide manufacturing, pharmaceutical preparations, infant food formulations, and battery production...
  2. TARGETED METAL CHELATORS FOR DIAGNOSTIC IMAGING
    Michael Welch; Fiscal Year: 2001
    ..The synthesis characterization and physicochemical studies will be carried out at Texas A&M University while the in vitro and in vivo evaluation of the pharmaceutical preparations will be undertaken at Washington University.
  3. Bi(III)-Initiated Chemistry: Mechanistic Investigations of Catalytic Activity
    Robert Hinkle; Fiscal Year: 2007
    ..In fact, bismuth compounds have been widely utilized in pharmaceutical preparations for over 400 years...
  4. LOW COST MODULES FOR PYROGEN-FREE WATER
    OLIVER MURPHY; Fiscal Year: 1993
    Water for pharmaceutical preparations and parenteral therapy must be of high chemical purity, sterile and free from fever producing bacterial endotoxins known as pyrogens. The removal of pyrogens from water by distillation is expensive...
  5. ANALYTICAL SERVICES CENTER FOR MEDICATIONS DEVELOPMENT
    Rodger Foltz; Fiscal Year: 2000
    ..The data generated by this contract will be utilized by the NIDA medications Development Division (MDD) in evaluating safety and efficacy of pharmaceutical preparations in the treatment of drug addictions.
  6. Label Free Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2007
    ..However, an anticounterfeiting method to protect pharmaceutical preparations directly at the pill level presents a singularly stringent set of requirements in terms of employing a ..
  7. IN VITRO ASSAY SYSTEMS FOR ANTIOXIDANT ACTIVITY
    Shanti Ghosh; Fiscal Year: 1999
    ..materials have a number of important applications, such as the evaluation of natural and synthetic pharmaceutical preparations, isolation of novel antioxidants from biological sources and early diagnosis of pathologies suspected ..
  8. PHARMACEUTICAL PREPARATIONS FOR ADDICTION TREATMENT
    Ram Murty; Fiscal Year: 2000
    ..The data and products generated by this contract will be utilized by the NIDA Medications Development Division (MDD) in developing and testing pharmaceutical preparations in the treatment of drug addictions.
  9. Countermeasures Against Chemical Threats [unreadable] Preclinical Development Facility
    Carol Green; Fiscal Year: 2009
    ..Development Facility will be part of a comprehensive research network and is designed to support a centralized facility for the advanced preclinical development of promising candidate pharmaceutical preparations.
  10. Countermeasures Against Chemical Threats [unreadable] Preclinical Development Facility
    Carol Green; Fiscal Year: 2010
    ..Development Facility will be part of a comprehensive research network and is designed to support a centralized facility for the advanced preclinical development of promising candidate pharmaceutical preparations.
  11. Pharmaceutical Anticounterfeiting Technology
    ROBERT HAUSHALTER; Fiscal Year: 2005
    ..has prevented any of these techniques from evolving into a widely used and effective system to protect pharmaceutical preparations. Parallel Synthesis Technologies proposes the use of an inexpensive and easy to use encoding technology,..
  12. OTHER FUNCTIONS: Development and Manufacture of Pharmaceutical Products for Addic
    Ram Murty; Fiscal Year: 2013
    The purpose of this contract is to carry out the development and manufacture of pharmaceutical preparations to be used in the medications development program of the National Institute on Drug Abuse (NIDA) for addiction treatment
  13. Development &Manufacture of Pharmaceutical Products for Addiction Treatment
    RAM B MURTY; Fiscal Year: 2009
    The purpose of this contract is to carry out the development &manufacture of pharmaceutical preparations to be used in the medications develoopment program of the National Institute on Drug Abuse (NIDA) for addiction treatment...
  14. Development & Manufacture of Pharmaceutical Products for Addiction Treatment
    RAM B MURTY; Fiscal Year: 2010
    The purpose of this contract is to carry out the development &manufacture of pharmaceutical preparations to be used in the medications development program of the National Institute on Drug Abuse (NIDA) for addiction treatment...
  15. CHROMATOGRAPHIC STUDIES OF FUNCTIONAL PROTEOMICS
    DAVID HAGE; Fiscal Year: 2009
    ..This, in turn, should allow an improved description of how the transport, metabolism, and effective dose of a drug will differ between a diabetic patient and an individual without diabetes. ..
  16. Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
    Leslie Benet; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  17. PH SENSITIVE COMPLEX HYDROGEL FOR PROTEIN DRUG RELEASE
    NIKOLAOS PEPPAS; Fiscal Year: 2001
    ..Finally, the insulin delivery efficacy of these novel devices will be tested using in vivo experiments. ..
  18. SYNERGISM AND MEDICATIONS DEVELOPMENT FOR DRUG ABUSE
    Ronald Tallarida; Fiscal Year: 2004
    ..This guide is the newest aim of this revised application. ..
  19. ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS
    Leslie Benet; Fiscal Year: 2002
    ....
  20. Prescription Drug Coverage and Health Outcomes in Elders
    Jennifer Tjia; Fiscal Year: 2008
    ..abstract_text> ..
  21. Analysis of Phenolic Phytochemical by ESI-MS
    Jennifer Brodbelt; Fiscal Year: 2003
    ....
  22. MECHANISMS OF TOXICITY GORDON CONFERENCE
    RONALD HINES; Fiscal Year: 2002
    ..There also is substantial involvement of new personnel as Chairs and co-Chairs. Thus, the Mechanism of Toxicity GRC is poised to continue its growth as the single leading small conference on Molecular Toxicology. ..
  23. Regulation of Hepatic Excretion of Xenobiotics by Mrps
    Curtis D Klaassen; Fiscal Year: 2010
    ..Elucidation of the role of Nrf2 in the regulation of the efflux transport process will have significant ramifications in toxicology, xenobiotics disposition, drug-drug interaction, and cancer chemoprevention. ..
  24. Modeling of Aerosol Transport in Alveolated Airways
    Chantal Darquenne; Fiscal Year: 2009
    ..The results of this study will provide a link to the mechanisms by which even seemingly modest PM exposure can cause or exacerbate lung disease and will also help to better design spatial targeting of inhaled drugs. ..
  25. 2006 Mechanisms in Toxicity Gordon Research Conference
    Mary Walker; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  26. EFFECTS OF DIOXIN ON CORONARY ANGIOGENESIS
    Mary Walker; Fiscal Year: 2002
    ..The research will help to elucidate a fundamental mechanism underlying TCDD-induced developmental toxicity, which can then be extrapolated to mammalian and human development. ..
  27. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  28. Vascularization of engineered cardiac tissue
    Robert Langer; Fiscal Year: 2008
    ..The vascularized constructs will be implanted and examined for integration with the host vasculature. We hypothesize that the vessel network created in vitro will promote the vascularization of the tissue in vivo. ..
  29. Using risk models to identify and prioritize outpatient 'high-alert' medications
    Michael Cohen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  30. Opening of the Blood Brain Barrier for Molecular Imaging
    Kullervo Hynynen; Fiscal Year: 2007
    ..The development of even one such imaging method for routine clinical use would have a major impact on patient care. [unreadable] [unreadable]..
  31. Optimizing NNRTI Doses in Patients with HIV and TB
    Terrence Blaschke; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  32. ULTRASOUND THERAPY DELIVERY THROUGH INTACT SKULL
    Kullervo Hynynen; Fiscal Year: 2002
    ..A successful implementation of even one of these possible therapies to routing clinical practice could have a major impact on patient care. ..
  33. Ah Receptor and Endothelin-Dependent Hypertension
    Mary K Walker; Fiscal Year: 2010
    ..Our results will define a novel regulatory pathway for suppression of hypoxia-induced ET- 1, which could be use to develop new therapies for ET-1-dependent cardiovascular diseases. ..
  34. A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
    JINDRICH H KOPECEK; Fiscal Year: 2010
    ..The concept of double-targeted macromolecular therapeutics provides a new paradigm for the design of efficient anticancer drugs for the treatment of ovarian cancer. ..
  35. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2001
    ..The stabilization of DNA in viable long-term pharmaceutical preparations is one critical part toward the advance of gene therapy to the clinic...
  36. ACUTE TOLERANCE IN ANESTHETIC ACTIONS AND INTERACTIONS
    Igor Kissin; Fiscal Year: 2001
    ....
  37. GPing: Informatics for Personal Control of Genomic Data
    Isaac S Kohane; Fiscal Year: 2010
    ..3: Design and evaluate a user interface to communicate disclosure. In concert with appropriate non-discrimination legislation, G-PING lays the groundwork for large-scale genomic cohort studies. ..
  38. Warfarin Pharmacogenetics in Pediatric Patients
    RONALD N contact HINES; Fiscal Year: 2010
    ..The IWPC clearly stated that additional research was needed with respect to the development of a similar algorithm for children and young adults. The proposed research will fill this important knowledge gap. ..
  39. Influence of eye pigmentation and diabetes on retinal drug delivery
    Uday B Kompella; Fiscal Year: 2010
    ..The findings of this study will be useful in developing drugs with enhanced transscleral delivery to the retina in order to treat diabetic retinopathy. ..
  40. Phased Array Ultrasound System for Cardiac Ablation
    Kullervo Hynynen; Fiscal Year: 2006
    ..This could result in significant cost savings and lead to a cure of thousands of patients. ..
  41. Correlative Multimodal Imaging of Cardiac Electrophysiology and Metabolism
    JOHN PETER contact WIKSWO; Fiscal Year: 2010
    ..This work will be a key step towards developing improved metabolic therapies. ..
  42. TREATMENT OF AGITATION IN THE NURSING HOME
    Jiska Cohen Mansfield; Fiscal Year: 2010
    ..PHS 398 (Rev. 05/01) Page 2 Principal Investigator/Program Director (Last, first, middle): Cohen-Mansfield, Jiska ..
  43. Pharmacogenetics of Methadone
    C Devane; Fiscal Year: 2003
    ..This study will form the basis for subsequent studies which should provide a more rational basis for dosing of methadone in pregnant addicts. ..
  44. Cell Therapy by In Vivo Fusion
    Markus Grompe; Fiscal Year: 2007
    ..Aim 3 is geared toward enhancing the efficiency of in vivo fusion and thereby increasing the number of bone marrow derived hepatocytes. Fusogenic viral envelope proteins will be used to artificially induce cell fusion. ..
  45. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2007
    ..Our best performing polymer-DNA formulations, identified in aims one and two, wilt be assayed in vivo in mice for 1) delivery efficiency, 2) specificity and biodistribution, and 3) complement activation and initial safety profile. ..
  46. In vitro substrate assay for multi-drug resistance
    DONALD MELCHIOR; Fiscal Year: 2005
    ..The Fluorosome-frans-pgp assay is adaptable to multiwell plate formats and robotics, for eventual moderate to high throughput screening of drug candidate libraries. ..
  47. 2005 GRC on Barrier Function of Mammalian Skin
    Gerald Kasting; Fiscal Year: 2005
    ..abstract_text> ..
  48. Environmental Hormones: Effects on Thyroid Function
    Curtis Klaassen; Fiscal Year: 2005
    ..abstract_text> ..
  49. Antisense imaging of brain gene expression in vivo
    William Pardridge; Fiscal Year: 2005
    ..This technology could be extended to humans and to other organs. At present, there is no parallel technology that enables the non-invasive in vivo imaging of "any gene in any person," which is the goal of this work. ..
  50. FASEB Conference: Mechanisms of Liver Growth and Disease
    Markus Grompe; Fiscal Year: 2004
    ..abstract_text> ..
  51. BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTER
    William Pardridge; Fiscal Year: 2003
    ..These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids. ..
  52. Isolation of Murine Pancreatic Liver Stem Cells
    Markus Grompe; Fiscal Year: 2004
    ..Monoclonal antibodies useful for FACS sorting of pancreatic cells will be generated. We will apply cell-sorting methods to enrich pancreatic liver stem cells. ..
  53. A Novel and Non-Invasive Method of Dermal Sampling
    Samir Mitragotri; Fiscal Year: 2003
    ..abstract_text> ..
  54. 2003 Barrier Function of Mammalian Skin Gordon Meeting
    Gerald Kasting; Fiscal Year: 2003
    ..It will hopefully lead to immediate, practical consequences for patients with skin and other disorders as well as to new insights into the origin and maintenance of mammalian barrier function. ..
  55. MICROCHIP DRUG DELIVERY SYSTEM
    Robert Langer; Fiscal Year: 2003
    ..abstract_text> ..
  56. Cutaneous Gene Therapy with Ultrasound: DNA Vaccination
    Samir Mitragotri; Fiscal Year: 2006
    ..3. Using an in vitro model, Epiderm, and in vivo mouse model, assess safety of skin exposure to low-frequency ultrasound. ..
  57. TARGETING TO LYMPHOCYTES MEDIATED BY SYNTHETIC EPITOPES
    Jindrich Kopecek; Fiscal Year: 2004
    ..The results of the proposed studies will provide a new method to treat human lymphomas. ..
  58. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  59. Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
    JAMES LEEDER; Fiscal Year: 2007
    ..abstract_text> ..
  60. GENE TRANSFER TO THE VASCULAR ENDOTHELIUM
    Theodore Friedmann; Fiscal Year: 2003
    ..Finally, we propose to characterize the biodistribution of these targeted vectors by sensitive fluorescence methods and correlate vector attachment with sites of endothelial-specific gene expression. ..
  61. Computer-aided Design of Anti-cancer Drugs Targeting Protein Kinases
    Chung Wong; Fiscal Year: 2006
    ..Specific Aim 5 applies this refined five-tier hierarchical model to identify new anti-cancer drug candidates for the protein kinase targets EGFR, HER2, CDK2, and BCR-ABL. [unreadable] [unreadable] [unreadable]..
  62. Index and Retrieval of Pathology Specimens
    Isaac Kohane; Fiscal Year: 2005
    ..abstract_text> ..
  63. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
    ..This work provides the basis for future drug discovery of AET blockers, which can be used as co-drugs to increase CNS penetration of HAART drugs. ..
  64. ANGIOGENESIS INHIBITORS FROM SHARK CARTILAGE
    Robert Langer; Fiscal Year: 2003
    ..After screening in the in vitro assays mentioned above, potential anti-angiogenic activity from shark cartilage will be assayed in vivo using the chick chonoallantoic assay and the rabbit corneal pocket assay. ..
  65. Biosensors for metabolic engineering
    Jay Keasling; Fiscal Year: 2006
    ..abstract_text> ..
  66. Differential Trust & Cancer Care within Black Subgroups
    LaVera Crawley; Fiscal Year: 2007
    ..By building on the strengths of national datasets, this study addresses several of the limitations of our current understanding of cancer prevention behaviors among black ethnic subgroups. ..
  67. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2002
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  68. TUMOR CELLS IN CIRCULATION
    Erkki Ruoslahti; Fiscal Year: 2001
    ..Finally, the ability to eliminate tumor cells from the circulation by sFN administration may provide additional protection against tumor cell transfer in bone marrow transplantation used to treat cancer and against tumor metastasis. ..
  69. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2007
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..